Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Nov 15, 2023 5:05pm
153 Views
Post# 35737901

RE:RE:Update

RE:RE:UpdateYes, agree, whatever they present going forward has to be grounded in a clearer path to revenue visibility.

I for one want to see them be operationally profitable, or on their way, so that:

1. We never have to worry about dilution ever again
2. There is more money going into pipelines to run clinicals and bring them to advanced license ready, and not administration
3. Sufficient funds to transition to a next generation CEO
4. To actually take a different strategy than just waiting for the next big pharma to come along. They could have bought a few Macdonalds from the outset and used that Big Mac profit to fund the pipelines, and had something more than status quo.

As we wait for the 1067 agreement to make them profitable, they have two choices, either wait around and pretend they are working or actually try something new. I for one have told them they should be selling laboratory services as "service" to help pay for lab equipment and staff. Geraldine is a world class scientist, who wouldn't pay.

As Elon Musk says, if you want to be successful, you have to be willing to sleep on the shop floor a few days a week.

They have both human and scientific capital/assets that are unexploited, and that should be put to work in full form in my opinion.






<< Previous
Bullboard Posts
Next >>